Medicare Part D spending · FDA facts · help paying
Serostim (somatropin): what Medicare Part D spends and the dated federal facts we hold
CMS's Medicare Part D spending dataset reports gross spending on Serostim of $109.52 million in 2024, across 5,396 claims and 612 beneficiaries. 1 non-manufacturing label change is dated in the last 12 months in the FDA's file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Serostim of $109.52 million in 2024, across 5,396 claims and 612 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $109.52 million | 5,396 | 612 | $20,296 |
| 2023 | $107.37 million | 5,192 | 604 | $20,680 |
| 2022 | $104.64 million | 5,433 | 597 | $19,259 |
| 2021 | $101.16 million | 5,560 | 623 | $18,195 |
| 2020 | $102.79 million | 6,139 | 693 | $16,744 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Biosimilar status
- Serostim; Zorbtive/Serostim (somatropin) is a reference product in the FDA Purple Book (BLA 020604, approved August 23, 1996). The Purple Book lists 0 biosimilars and 0 interchangeable products that name it as their reference product.
This is what the FDA Purple Book lists on the read date. It is a record, not a forecast of when any product will launch or be substituted.
Source: FDA Purple Book (purplebook-2026-10), read November 7, 2026. Purple Book data file.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 8 designations for Somatropin, 5 with an approval recorded. The 6 most recent are shown. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| August 9, 2006 | Treatment of short stature in patients with Noonan syndrome | Designated/Approved | Novo Nordisk Inc. |
| December 15, 2005 | Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency | Designated/Approved | Eli Lilly and Company |
| March 16, 2004 | Treatment of patients with HIV-associated adipose redistribution syndrome | Designated | EMD Serono, Inc. |
| September 6, 1994 | Treatment of adults with growth hormone deficiency. | Designated/Approved | Pharmacia & Upjohn |
| February 12, 1993 | Treatment of cachexia associated with AIDS. | Designated/Designation Withdrawn or Revoked | Bio-Technology General Corp. |
| May 8, 1990 | Treatment of short stature associated with Turner syndrome. | Designated/Approved | Eli Lilly and Company |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2024, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 2 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| CA | 130 | $2,074,170 | All record types |
| NY | 86 | $1,704,018 | All record types |
A state missing from the table means its figures were suppressed or not reported, not zero use.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2024, modified 2026-07-13T15:37:28Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Medicaid spending
CMS's Medicaid spending dataset reports $7.84 million for Serostim in 2024. CMS's dataset states spending includes Federal and State reimbursement and dispensing fees and is not reduced by Medicaid rebates paid to the states. Spending is what Medicaid paid, not what a patient pays.
| Year | Spending | Claims |
|---|---|---|
| 2024 | $7.84 million | 456 |
| 2023 | $9.26 million | 535 |
| 2022 | $11.54 million | 686 |
| 2021 | $11.80 million | 713 |
| 2020 | $11.93 million | 783 |
Source: CMS Medicaid spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. A national drug-level aggregate; it says nothing about any state's coverage rules.
Federal formulary status
TRICARE
The Defense Health Agency's TRICARE formulary files include 3 packages of Serostim in the uniform formulary class GROWTH STIMULATING AGENTS. Each row counts packages by the list that names them and the status it gives. A status is a TRICARE listing, not a statement about what a plan will pay for you.
| List | Status | Packages |
|---|---|---|
| Non-Formulary Drug List | NON-FORMULARY | 3 |
| Tier 4 / Not Covered Drug List | NOT COVERED | 3 |
Source: TRICARE formulary files (tricare-formulary-2026-10), read November 7, 2026. TRICARE formulary page.
VA national formulary
The VA's national formulary files list the ingredient somatropin, which covers every maker's product with that ingredient, not only Serostim. Each row is a VA national drug file entry and its status.
| VA entry | Status | Active NDCs |
|---|---|---|
| SOMATROPIN INJ | Non-formulary | 33 |
Source: VA Pharmacy Benefits Management national formulary (va-formulary-2026-09), read November 7, 2026. VA formulary page.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
FDA actions on the applications behind Serostim dated since November 11, 2025, leaving out manufacturing (CMC) changes. 1 change in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| July 14, 2026 | Labeling | BLA020604 | 104 | Label (PDF) posted July 29, 2026FDA letter posted July 15, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Questions
Does Medicare have a negotiated price for Serostim?
The CMS negotiated-price file we read does not list Serostim, so this page shows no negotiated price. A drug appears in that file only when CMS selects it for negotiation, and not being listed says nothing about what it costs a patient.
Is there help paying for Serostim?
No program in our finder lists this drug yet.
How much does Medicare Part D spend on Serostim?
CMS's Medicare Part D spending dataset reports gross spending on Serostim of $109.52 million in 2024, across 5,396 claims and 612 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns the generic-entry upper bound, label history, recalls, trials, assistance and Part D spending, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/serostim.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. This drug is not in the CMS negotiated-price file, so no price source is used. Program details read from each program's own pages; CMS Medicare Part D spending by drug; CMS Medicaid spending by drug; TRICARE and VA formulary files; FDA Purple Book; FDA Drugs@FDA and Orange Book data files. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.